Long-term safety and efficacy of subcutaneous pasireotide in patients with Cushing’s disease: interim results from a long-term real-world evidence study

被引：0
作者：
Luca Manetti
Timo Deutschbein
Jochen Schopohl
Kevin C. J. Yuen
Michael Roughton
Ulrike Kriemler-Krahn
Libuse Tauchmanova
Ricardo Maamari
Carla Giordano
机构：
[1] Università di Pisa,Azienda Ospedaliero
[2] University of Würzburg,Universitaria Pisana, Dipartimento di Medicina Clinica e Sperimentale
[3] Ludwig-Maximilians-Universität München,Division of Endocrinology and Diabetes, Department of Internal Medicine I, University Hospital
[4] Swedish Neuroscience Institute,Medizinische Klinik und Poliklinik IV
[5] Barrow Neurological Institute,Swedish Pituitary Center
[6] Novartis Pharma AG,Section of Endocrinology, Diabetology and Metabolism, Department of Health Promotion Sciences Maternal and Infantile Care, Internal Medicine and Medical Specialities (PROMISE)
[7] Novartis Pharmaceuticals Corporation,undefined
[8] University of Palermo,undefined
来源：
Pituitary | 2019年 / 22卷
关键词：
Cushing’s disease; Pasireotide; Hypercortisolism; Pituitary; Safety;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：542 / 551
页数：9
相关论文
共 154 条
[1]  
Lacroix A(2015)Cushing’s syndrome Lancet 386 913-927
[2]  
Feelders RA(2016)Complications of Cushing’s syndrome: state of the art Lancet Diabetes Endocrinol 4 611-629
[3]  
Stratakis CA(2015)The treatment of Cushing’s disease Endocr Rev 36 385-486
[4]  
Nieman LK(2018)Pasireotide versus pituitary surgery: a retrospective analysis of 12 months of treatment in patients with Cushing’s disease Endocrine 59 454-457
[5]  
Pivonello R(2015)Treatment of Cushing’s syndrome: an Endocrine Society clinical practice guideline J Clin Endocrinol Metab 100 2807-2831
[6]  
Isidori AM(2002)SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile Eur J Endocrinol 146 707-716
[7]  
De Martino MC(2012)A 12-month Phase 3 study of pasireotide in Cushing’s disease N Engl J Med 366 914-924
[8]  
Newell-Price J(2015)Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing’s disease: results from an open-ended, open-label extension trial Pituitary 18 604-612
[9]  
Biller BMK(2014)Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing’s disease: results from a Phase III study Clin Endocrinol (Oxf) 81 408-417
[10]  
Colao A(2018)Pasireotide treatment reduces cardiometabolic risk in Cushing’s disease patients: an Italian, multicenter study Endocrine 61 118-124
12345678910